 |
|
|
| |
Prevalence, Treatment, and Comorbidities of Hepatitis C Infection (HCV) Among Patients With Commercial and Medicaid Insurance
|
| |
| |
Reported by Jules Levin
DDW May 18-21 2013 Orlando Florida
EASL: Direct and indirect cost burden is higher in HCV infection compared with a matched non-HCV infected cohort in a privately-insured population - (05/07/13)
EASL: Patient characteristics and utilization of protease inhibitors in hepatitis C virus (HCV) patients in a large payer database - (05/07/13)
Jennifer M Griffith, PharmD1, Woodie M Zachry, III, PhD1, Kathleen Lang, PhD2, Christine Nichols, BA2, Lakshmi P Kandukuri1, Oscar A Hayes, MS1
1AbbVie Inc., North Chicago, Illinois, United States; 2Boston Health Economics, Inc., Waltham, Massachusetts, United States
|
| |
|
|
|
|
|
